Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Princess Margaret Hospital, Canada
Ortho Biotech, Inc.
Information provided by (Responsible Party):
University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT00570180
First received: December 6, 2007
Last updated: March 4, 2016
Last verified: March 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: September 2016
  Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)